Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 3 2Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 4Skin Neoplasms 3Skin Diseases 2Neoplasm Metastasis 2Neoplasms 1Low-grade Serous Ovarian Cancer 1Colorectal Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Leucovorin 22Fluorouracil 22Paclitaxel 21Gemcitabine 21Docetaxel 21Capecitabine 21Irinotecan 16Carboplatin 15Radiosurgery 14Oxaliplatin 13Cisplatin 13Bevacizumab 13Zoledronic Acid 12pembrolizumab 11Radiotherapy 11Fulvestrant 11palbociclib 9Pemetrexed 9Drug Therapy 9130-nm albumin-bound paclitaxel 9Surgical Procedures, Operative 7Letrozole 7Ibandronic Acid 7abemaciclib 6Trastuzumab 6Prednisone 6Vinorelbine 5Folfox protocol 5Floxuridine 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoplasm Metastasis × binimetinib × Clear all
NCT01909453 2026-02-27

COLUMBUS

Pfizer

Phase 3 Completed
921 enrolled 48 charts 1 FDA
Dermatologic

Melanoma, Neoplasm Metastasis, Neoplasms, Skin Diseases, Skin Neoplasms

NCT01763164 2021-03-22

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Pfizer

Phase 3 Completed
402 enrolled 21 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡